GoodRx Holdings, Inc.
GDRXNASDAQHealthcare● Active
$2.65
$-0.20(-7.02%)
Market Cap$918568374
P/E Ratio—
52W High$5.81
52W Low$1.77
GoodRx Holdings, Inc. (GDRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GDRX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.07
Est. $0.07 · +0.0%
Revenue
$0.19B
Est. $0.19B · +4.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
GDRX reports quarterly as a NASDAQ-listed Medical - Healthcare Information Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.08 | — | — | — | $0.19B | — |
| — Q2 FY2026 | May 6, 2026 | $0.07 | $0.07 | +0.0% | $0.19B | $0.19B | +4.6% |
| — Q1 FY2026 | Feb 25, 2026 | $0.09 | $0.09 | +0.0% | $0.19B | $0.19B | +0.8% |
| ▼ Q4 FY2025 | Nov 4, 2025 | $0.09 | $0.08 | -11.1% | $0.20B | $0.19B | +1.4% |
| ▼ Q3 FY2025 | Aug 6, 2025 | $0.10 | $0.09 | -10.0% | $0.20B | $0.21B | -1.1% |
| — Q2 FY2025 | May 7, 2025 | $0.09 | $0.09 | +0.0% | $0.20B | $0.20B | +0.4% |
| ▼ Q1 FY2025 | Feb 27, 2025 | $0.10 | $0.09 | -10.0% | $0.20B | $0.20B | -0.6% |
| ▼ Q4 FY2024 | Nov 7, 2024 | $0.09 | $0.08 | -11.1% | $0.20B | $0.20B | -2.5% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026
EPS Actual
$0.07
EPS Est.
$0.07
EPS Surpr.
+0.0%
Revenue
$0.19B
Q1 FY2026
Feb 25, 2026
EPS Actual
$0.09
EPS Est.
$0.09
EPS Surpr.
+0.0%
Revenue
$0.19B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
$0.08
EPS Est.
$0.09
EPS Surpr.
-11.1%
Revenue
$0.20B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
$0.09
EPS Est.
$0.10
EPS Surpr.
-10.0%
Revenue
$0.20B
Q2 FY2025
May 7, 2025
EPS Actual
$0.09
EPS Est.
$0.09
EPS Surpr.
+0.0%
Revenue
$0.20B
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
$0.09
EPS Est.
$0.10
EPS Surpr.
-10.0%
Revenue
$0.20B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
$0.08
EPS Est.
$0.09
EPS Surpr.
-11.1%
Revenue
$0.20B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.12 | $0.13 | $0.13 | 5 |
| Q3 FY2028 | $0.13 | $0.13 | $0.13 | 5 |
| Q2 FY2028 | $0.12 | $0.12 | $0.13 | 6 |
| Q1 FY2028 | $0.10 | $0.11 | $0.11 | 3 |
| Q4 FY2027 | $0.10 | $0.10 | $0.10 | 2 |
| Q3 FY2027 | $0.10 | $0.10 | $0.10 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2028 | $0.2B | $0.2B | $0.2B | 5 |
| Q2 FY2028 | $0.2B | $0.2B | $0.2B | 3 |
| Q1 FY2028 | $0.2B | $0.2B | $0.2B | 3 |
| Q4 FY2027 | $0.2B | $0.2B | $0.2B | 4 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +0.0% | $2.56 | $2.57 | +0.39% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +0.0% | $2.37 | $2.45 | +3.38% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -11.1% | $3.31 | $3.26 | -1.51% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -10.0% | $4.39 | $4.34 | -1.14% |
| ▲ Q2 FY2025 | May 7, 2025 | +0.0% | $4.26 | $3.79 | -11.03% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -10.0% | $4.89 | $4.98 | +1.84% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -11.1% | $6.11 | $5.04 | -17.51% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -11.1% | $8.61 | $7.01 | -18.58% |
Q2 FY2026+0.39%
Report Date
May 6, 2026
EPS Beat/Miss
+0.0%
Price Before
$2.56
Price After
$2.57
Q1 FY2026+3.38%
Report Date
Feb 25, 2026
EPS Beat/Miss
+0.0%
Price Before
$2.37
Price After
$2.45
Q4 FY2025-1.51%
Report Date
Nov 4, 2025
EPS Beat/Miss
-11.1%
Price Before
$3.31
Price After
$3.26
Q3 FY2025-1.14%
Report Date
Aug 6, 2025
EPS Beat/Miss
-10.0%
Price Before
$4.39
Price After
$4.34
Q2 FY2025-11.03%
Report Date
May 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$4.26
Price After
$3.79
Q1 FY2025+1.84%
Report Date
Feb 27, 2025
EPS Beat/Miss
-10.0%
Price Before
$4.89
Price After
$4.98
Q4 FY2024-17.51%
Report Date
Nov 7, 2024
EPS Beat/Miss
-11.1%
Price Before
$6.11
Price After
$5.04
Q3 FY2024-18.58%
Report Date
Aug 8, 2024
EPS Beat/Miss
-11.1%
Price Before
$8.61
Price After
$7.01
Avg Beat Reaction-2.42%
Avg Miss Reaction-7.38%
Beat Rate3 / 8 quarters
Largest Move-18.58% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GDRX ends December
GoodRx Holdings, Inc. (GDRX) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.07 (in line with the analyst consensus of $0.07). GDRX has beaten EPS estimates for 2 consecutive quarters. The next GDRX earnings date is expected around September 1, 2026.
Each quarter, investors track GDRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GDRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GDRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GDRX earnings · 4 questionsGoodRx Holdings, Inc.'s next earnings report is expected around September 1, 2026. GDRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GDRX historically reports after market close (AMC).
GDRX earnings datewhen is GDRX earningsGDRX next earnings datewhen does GDRX report earningsGDRX earnings calendar
▸ Source: FMP · GoodRx Holdings, Inc. SEC filings · US GAAP · GoodRx Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026